Literature DB >> 7616162

3,5-Di-iodo-L-thyronine suppresses TSH in rats in vivo and in rat pituitary fragments in vitro.

C Horst1, A Harneit, H J Seitz, H Rokos.   

Abstract

3,5-Di-iodo-L-thyronine (T2) is a naturally occurring metabolite of thyroxine (T4). Contrary to earlier findings, T2 has recently been shown to have rapid effects in rat liver and in mononuclear blood cells. In the experiments described here, T2 was tested to determine whether it has a TSH suppressive effect in rats in vivo and in rat pituitary fragments in vitro. In experiments over 2 weeks in rats in vivo, low doses of T2 (20-200 micrograms/100 g body weight per day) had no significant influence on body and organ weights, but significantly decreased TSh and T4 serum concentrations. At 200 micrograms/100 g per day, T2 suppressed TSH to 43% and T4 to 29% of control levels. At 1-15 micrograms/100 g per day, 3,5,3'-tri-iodo-L-thyronine (T3), used as a comparison to T2, had significant effects on TSH and T4 levels, and also on body weight. Fifteen micrograms T3/100 g per day decreased TSH to 44%, T4 to 25%, and body weight to 59% of control levels. In experiments over 3 months in rats in vivo, a low dose (25 micrograms/100 g per day) of T2 suppressed TSH to 60% and T4 to 57% of control levels and had no significant influence on other parameters. Conversely, 0.1 microgram/100 g per day T3 had significant effects on body and organ weights as well as pellet intake, but a less pronounced TSH suppressive effect: TSH concentrations were unchanged and T4 concentrations were down to 80% of control values.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7616162     DOI: 10.1677/joe.0.1450291

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  9 in total

Review 1.  Control of energy metabolism by iodothyronines.

Authors:  A Lanni; M Moreno; A Lombardi; P de Lange; F Goglia
Journal:  J Endocrinol Invest       Date:  2001-12       Impact factor: 4.256

2.  Translating pharmacological findings from hypothyroid rodents to euthyroid humans: is there a functional role of endogenous 3,5-T2?

Authors:  Maik Pietzner; Ina Lehmphul; Nele Friedrich; Claudia Schurmann; Till Ittermann; Marcus Dörr; Matthias Nauck; René Laqua; Uwe Völker; Georg Brabant; Henry Völzke; Josef Köhrle; Georg Homuth; Henri Wallaschofski
Journal:  Thyroid       Date:  2014-11-24       Impact factor: 6.568

Review 3.  Tissue thyroid hormones and thyronamines.

Authors:  Alice Accorroni; Federica Saponaro; Riccardo Zucchi
Journal:  Heart Fail Rev       Date:  2016-07       Impact factor: 4.214

4.  3,5-Diiodo-L-Thyronine Exerts Metabolically Favorable Effects on Visceral Adipose Tissue of Rats Receiving a High-Fat Diet.

Authors:  Elena Silvestri; Rosalba Senese; Federica Cioffi; Rita De Matteis; Davide Lattanzi; Assunta Lombardi; Antonia Giacco; Anna Maria Salzano; Andrea Scaloni; Michele Ceccarelli; Maria Moreno; Fernando Goglia; Antonia Lanni; Pieter de Lange
Journal:  Nutrients       Date:  2019-01-27       Impact factor: 5.717

5.  A Thyroid Hormone-Independent Molecular Fingerprint of 3,5-Diiodothyronine Suggests a Strong Relationship with Coffee Metabolism in Humans.

Authors:  Maik Pietzner; Josef Köhrle; Ina Lehmphul; Kathrin Budde; Gabi Kastenmüller; Georg Brabant; Henry Völzke; Anna Artati; Jerzy Adamski; Uwe Völker; Matthias Nauck; Nele Friedrich; Georg Homuth
Journal:  Thyroid       Date:  2019-11-11       Impact factor: 6.568

6.  3,5-T2-A Janus-Faced Thyroid Hormone Metabolite Exerts Both Canonical T3-Mimetic Endocrine and Intracrine Hepatic Action.

Authors:  Josef Köhrle; Ina Lehmphul; Maik Pietzner; Kostja Renko; Eddy Rijntjes; Keith Richards; João Anselmo; Mark Danielsen; Jacqueline Jonklaas
Journal:  Front Endocrinol (Lausanne)       Date:  2020-01-08       Impact factor: 5.555

7.  Potential Applications of Thyroid Hormone Derivatives in Obesity and Type 2 Diabetes: Focus on 3,5-Diiodothyronine (3,5-T2) in Psammomys obesus (Fat Sand Rat) Model.

Authors:  Asma Bouazza; Roland Favier; Eric Fontaine; Xavier Leverve; Elhadj-Ahmed Koceir
Journal:  Nutrients       Date:  2022-07-25       Impact factor: 6.706

Review 8.  3,5-T2-an Endogenous Thyroid Hormone Metabolite as Promising Lead Substance in Anti-Steatotic Drug Development?

Authors:  Rajas Sane; Eva K Wirth; Josef Köhrle
Journal:  Metabolites       Date:  2022-06-23

9.  Administration of 3,5-diiodothyronine (3,5-T2) causes central hypothyroidism and stimulates thyroid-sensitive tissues.

Authors:  Alvaro Souto Padron; Ruy Andrade Louzada Neto; Thiago Urgal Pantaleão; Maria Carolina de Souza dos Santos; Renata Lopes Araujo; Bruno Moulin de Andrade; Monique da Silva Leandro; João Pedro Saar Werneck de Castro; Andrea Claudia Freitas Ferreira; Denise Pires de Carvalho
Journal:  J Endocrinol       Date:  2014-04-01       Impact factor: 4.286

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.